Fluvastatin Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Retraction Note: Fluvastatin-Loaded Emulsomes Exhibit Improved Cytotoxic and Apoptosis in Prostate Cancer Cells
AAPS PharmSciTech. 2023 Jun 2;24(5):128. doi: 10.1208/s12249-023-02591-y.NO ABSTRACTPMID:37266798 | DOI:10.1208/s12249-023-02591-y (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - June 2, 2023 Category: Drugs & Pharmacology Authors: Nabil A Alhakamy Shaimaa M Badr-Eldin Hibah M Aldawsari Anas Alfarsi Thikryat Neamatallah Solomon Z Okbazghi Usama A Fahmy Osama A A Ahmad Basma G Eid Wael Ali Mahdi Adel F Alghaith Sultan Alshehri Shadab Md Source Type: research

Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies —Analysis of the WHO Pharmacovigilance Database
ConclusionRhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 28, 2023 Category: Cardiology Source Type: research

Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study
ConclusionsPersistent statin use can reduce cardiovascular mortality in patients with T2DM; in particular, the higher is the cDDD-year of statin, the lower is the cardiovascular mortality. The optimal statin dose daily was 0.86 DDD. The priority of protective effects on mortality are pitavastatin, rosuvastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, and lovastatin for the statin users compared with non-statin users. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Source Type: research

Cancers, Vol. 15, Pages 2020: Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
Marie-Cécile Le Deley Gauthier Bouche Nicolas André Preclinical data support the activity of celecoxib and fluvastatin in high-grade (HGG) and low-grade gliomas (LGG). A phase I trial (NCT02115074) was designed to evaluate the safety of this combination in children with refractory/relapsed HGG and LGG using four dose levels of fluvastatin with a fixed daily dose of celecoxib. A Continual Reassessment Method was used for fluvastatin dose escalation. Dose-limiting toxicities (DLT) were determined on the first treatment cycle. Twenty patients were included. Ten LGG and ten HGG patients received a median of 3.5 trea...
Source: Cancers - March 28, 2023 Category: Cancer & Oncology Authors: Pierre Leblond Emmanuelle Tresch-Bruneel Alicia Probst Nad ège Néant Caroline Solas Arthur Sterin Thomas Boulanger Isabelle Aerts C écile Faure-Conter Anne-Isabelle Bertozzi Pascal Chastagner Natacha Entz-Werl é Emilie De Carli Marie-C écile Le Deley Tags: Article Source Type: research

Molecules, Vol. 28, Pages 2808: One-Step Microwell Plate-Based Spectrofluorimetric Assay for Direct Determination of Statins in Bulk Forms and Pharmaceutical Formulations: A Green Eco-Friendly and High-Throughput Analytical Approach
This study describes the development of a one-step microwell spectrofluorimetric assay (MW-SFA) with high sensitivity and throughput for the determination of four statins in their pharmaceutical and formulations (tablets). These statins were pitavastatin (PIT), fluvastatin (FLU), rosuvastatin (ROS) and atorvastatin (ATO). The MW-SFA involves the measurement of the native fluorescence of the statin aqueous solutions. The assay was conducted in white opaque 96-microwell plates, and the fluorescence intensities of the solutions were measured by using a fluorescence microplate reader. The optimum conditions of the assay were e...
Source: Molecules - March 20, 2023 Category: Chemistry Authors: Ibrahim A. Darwish Hany W. Darwish Nourah Z. Alzoman Awadh M. Ali Tags: Article Source Type: research

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs
Pharmacol Res. 2023 Mar 10:106724. doi: 10.1016/j.phrs.2023.106724. Online ahead of print.ABSTRACTOrganic anion transporting polypeptide 2B1 (OATP2B1/SLCO2B1) facilitates uptake transport of structurally diverse endogenous and exogenous compounds. To investigate the roles of OATP2B1 in physiology and pharmacology, we established and characterized Oatp2b1 knockout (single Slco2b1-/- and combination Slco1a/1b/2b1-/-) and humanized hepatic and intestinal OATP2B1 transgenic mouse models. While viable and fertile, these strains exhibited a modestly increased body weight. In males, unconjugated bilirubin levels were markedly red...
Source: Cancer Control - March 12, 2023 Category: Cancer & Oncology Authors: Wenlong Li Dilek Iusuf Rolf W Sparidans Els Wagenaar Yaogeng Wang Dirk R de Waart Margarida L F Martins St éphanie van Hoppe Maria C Lebre Olaf van Tellingen Jos H Beijnen Alfred H Schinkel Source Type: research

Statin associated Muscular Adverse Effects
CONCLUSION: Early recognition of muscle symptoms is required to prevent rhabdomyolysis. Further researchare needed to completely elucidate the pathophysiology of statin-induced muscular adverse effects.PMID:36847228 | DOI:10.2174/1574886318666230227143627 (Source: Current Drug Safety)
Source: Current Drug Safety - February 27, 2023 Category: Drugs & Pharmacology Authors: Rania Kammoun Ons Charfi Ghozlane Lakhoua Ahmed Zaiem Riadh Daghfous Sarrah Kastalli Imen Aouinti Sihem El Aidli Source Type: research

Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth of murine enteroids
We examined the impact of statins on protein kinase D (PKD) activation by G protein-coupled receptor (GPCR) agonists. Treatment of intestinal IEC-18 cells with cerivastatin inhibited PKD auto-phosphorylation at Ser916 induced by angiotensin II (ANG II) or vasopressin in a dose-dependent manner with half-maximal inhibition at 0.2 mM. Cerivastatin treatment inhibited PKD activation stimulated by these agonists for different times (5-60min) and blunted HDAC5 phosphorylation, a substrate of PKD. Other lipophilic statins, including simvastatin, atorvastatin and fluvastatin also prevented PKD activation in a dose-dependent manne...
Source: American Journal of Physiology. Cell Physiology - February 13, 2023 Category: Cytology Authors: James Sinnett-Smith M Eugenia Torres-Marquez Jen-Kuan Chang Yuki Shimizu Fang Hao Martin G Martin Enrique Rozengurt Source Type: research

Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth of murine enteroids
We examined the impact of statins on protein kinase D (PKD) activation by G protein-coupled receptor (GPCR) agonists. Treatment of intestinal IEC-18 cells with cerivastatin inhibited PKD auto-phosphorylation at Ser916 induced by angiotensin II (ANG II) or vasopressin in a dose-dependent manner with half-maximal inhibition at 0.2 mM. Cerivastatin treatment inhibited PKD activation stimulated by these agonists for different times (5-60min) and blunted HDAC5 phosphorylation, a substrate of PKD. Other lipophilic statins, including simvastatin, atorvastatin and fluvastatin also prevented PKD activation in a dose-dependent manne...
Source: Am J Physiol Cell Ph... - February 13, 2023 Category: Cytology Authors: James Sinnett-Smith M Eugenia Torres-Marquez Jen-Kuan Chang Yuki Shimizu Fang Hao Martin G Martin Enrique Rozengurt Source Type: research